Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

Correlation between preoperative peripheral blood NLR, PLR, LMR and prognosis of patients with head and neck squamous cell carcinoma

Authors: Jiao Zhou, Sheng Wei, Xiumei Guo, Yanjun Huang, Yizheng Zhang, Yuming Hong, Xiaofang Chen, Ming Lu, Feng Zheng, Chaohui Zheng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Markers that can be used to evaluate the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) remain undefined.

Objective

This study aimed to investigate the prognostic impact of preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in patients with HNSCC who underwent surgery-based treatment for the first time.

Methods

This retrospective study included patients HNSCC who underwent surgery-based treatment at our institution between January 2018 and December 2020. Specificity and sensitivity were analyzed using receiver operating characteristic (ROC) curves and the critical value was determined. Patients were divided into low and high groups according to NLR, PLR, and LMR the critical value. Log-rank and Cox proportional hazards models were used to evaluate the associations between preoperative NLR, PLR, LMR, and overall survival (OS).

Results

A total of 304 patients with HNSCC were included, of whom 190 (62.5%) and 114 (37.5%), 203 (66.8%) and 101 (33.2%), 98 (32.2%), and 206 (67.8%) cases were classified as low NLR and high NLR groups, low PLR and high PLR groups, and low LMR and high LMR groups, respectively. Univariate analysis showed that white blood cell count (WBC), neutrophil count (NEU), platelet count (PLT), NLR, pathologic N stage (pN stage), TNM stage and postoperative complications were significantly associated with OS (p < 0.05). Multivariate analysis showed that NEU, NLR, TNM stage and postoperative complications were independent negative prognostic factors for HNSCC (p < 0.05).

Conclusion

Preoperative NLR is an independent negative prognostic factor for HNSCC. Patients with an increased NLR may have a poor OS.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Curado MP, Hashibe M. Recent changes in the epidemiology of Head and Neck cancer[J]. Curr Opin Oncol. 2009;21(3):194–200.CrossRefPubMed Curado MP, Hashibe M. Recent changes in the epidemiology of Head and Neck cancer[J]. Curr Opin Oncol. 2009;21(3):194–200.CrossRefPubMed
3.
go back to reference Mascarella MA, Mannard E, Sabrina DSW, et al. Neutrophil-to-lymphocyte ratio in Head and Neck cancer prognosis: a systematic review and meta-analysis[J]. Head & Neck; 2018;40. pp. 2546–57. 11. Mascarella MA, Mannard E, Sabrina DSW, et al. Neutrophil-to-lymphocyte ratio in Head and Neck cancer prognosis: a systematic review and meta-analysis[J]. Head & Neck; 2018;40. pp. 2546–57. 11.
4.
go back to reference Mariani P, Russo D, Maisto M, et al. Pre-treatment neutrophil-to-lymphocyte ratio is an Independent prognostic factor in head and neck squamous cell carcinoma: Meta-analysis and trial sequential analysis. J Oral Pathol Med. 2022;51(1):39–51.CrossRefPubMed Mariani P, Russo D, Maisto M, et al. Pre-treatment neutrophil-to-lymphocyte ratio is an Independent prognostic factor in head and neck squamous cell carcinoma: Meta-analysis and trial sequential analysis. J Oral Pathol Med. 2022;51(1):39–51.CrossRefPubMed
5.
go back to reference Inflammation and cancer[J]. Ann Afr Med. 2019 Jul-Sep;18(3):121–6. Inflammation and cancer[J]. Ann Afr Med. 2019 Jul-Sep;18(3):121–6.
6.
go back to reference Rajesh S, Kumar MM, Himanshu A. Inflammation, Immunity, and Cancer[J]. Mediators of Inflammation, 2017; 2017:1–1. Rajesh S, Kumar MM, Himanshu A. Inflammation, Immunity, and Cancer[J]. Mediators of Inflammation, 2017; 2017:1–1.
8.
go back to reference Zhao H, Wu L, Yan G, et al. Inflammation and Tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.CrossRefPubMedPubMedCentral Zhao H, Wu L, Yan G, et al. Inflammation and Tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.CrossRefPubMedPubMedCentral
9.
go back to reference Balkwill F, Mantovani A. Inflammation and cancer: back to Vir-chow [J] Lancet, Singh N, Baby D. Rajguru J P. Balkwill F, Mantovani A. Inflammation and cancer: back to Vir-chow [J] Lancet, Singh N, Baby D. Rajguru J P.
10.
go back to reference Virchow R. An address on the value of pathological Experiments[J]. BMJ, 1881; 2(1075):198–203. Virchow R. An address on the value of pathological Experiments[J]. BMJ, 1881; 2(1075):198–203.
11.
go back to reference Bass DA, Parce JW, Dechatelet LR, et al. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation[J]. J Immunol. 1983;130(4):1910–7.CrossRefPubMed Bass DA, Parce JW, Dechatelet LR, et al. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation[J]. J Immunol. 1983;130(4):1910–7.CrossRefPubMed
12.
go back to reference Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutro-phil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis[J]. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12.CrossRefPubMed Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutro-phil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis[J]. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12.CrossRefPubMed
13.
go back to reference Ishibashi Y, Tsujimoto H, Yaguchi Y et al. Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta-analysis[J]. Annals of Gastroenterological Surgery, 2019; 21;4(1):56–63. Ishibashi Y, Tsujimoto H, Yaguchi Y et al. Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta-analysis[J]. Annals of Gastroenterological Surgery, 2019; 21;4(1):56–63.
14.
go back to reference Gu X, Gao X, Li X, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in Prostate cancer: evidence from 16,266 patients[J]. Sci Rep. 2016;25(6):22089.CrossRef Gu X, Gao X, Li X, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in Prostate cancer: evidence from 16,266 patients[J]. Sci Rep. 2016;25(6):22089.CrossRef
15.
go back to reference Wang Y, Peng C, Cheng Z, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis - ScienceDirect[J]. Int J Surg. 2018;55:73–80.CrossRefPubMed Wang Y, Peng C, Cheng Z, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis - ScienceDirect[J]. Int J Surg. 2018;55:73–80.CrossRefPubMed
16.
go back to reference Szor DJ, Dias AR, Pereira MA, et al. Prognostic role of Neutrophil/Lymphocyte ratio in Resected gastric Cancer: a systematic review and Meta-analysis[J]. Clinics. 2018;73:360.CrossRef Szor DJ, Dias AR, Pereira MA, et al. Prognostic role of Neutrophil/Lymphocyte ratio in Resected gastric Cancer: a systematic review and Meta-analysis[J]. Clinics. 2018;73:360.CrossRef
17.
go back to reference Shao Y, Wu B, Jia W, et al. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis[J]. BMC Urol. 2020;20(1):90.CrossRefPubMedPubMedCentral Shao Y, Wu B, Jia W, et al. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis[J]. BMC Urol. 2020;20(1):90.CrossRefPubMedPubMedCentral
18.
go back to reference Miyahara Y, Takashi S, Shimizu Y, et al. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer[J]. World J Surg Oncol. 2020;18(1):78.CrossRefPubMedPubMedCentral Miyahara Y, Takashi S, Shimizu Y, et al. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer[J]. World J Surg Oncol. 2020;18(1):78.CrossRefPubMedPubMedCentral
19.
go back to reference Ishibashi Y, Tsujimoto H, Sugasawa H, et al. Prognostic value of platelet-related measures for overall survival in esophageal squamous cell carcinoma: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol. 2021;164:103427.CrossRefPubMed Ishibashi Y, Tsujimoto H, Sugasawa H, et al. Prognostic value of platelet-related measures for overall survival in esophageal squamous cell carcinoma: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol. 2021;164:103427.CrossRefPubMed
20.
go back to reference Takenaka Y, Oya R, Kitamiura T, et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis[J]. Head & Neck; 2018;40. pp. 2714–23. 12. Takenaka Y, Oya R, Kitamiura T, et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis[J]. Head & Neck; 2018;40. pp. 2714–23. 12.
21.
go back to reference Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: Prognostic significance and meta-analysis[J]. Clinica Chimica Acta, 2018; 2018:142–146. Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: Prognostic significance and meta-analysis[J]. Clinica Chimica Acta, 2018; 2018:142–146.
23.
go back to reference Huang SH, O’Sullivan B. Overview of the 8th Edition TNM classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18(7):40.CrossRefPubMed Huang SH, O’Sullivan B. Overview of the 8th Edition TNM classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18(7):40.CrossRefPubMed
24.
go back to reference Sun H, Yin CQ, Liu Q, Wang F, Yuan CH. Clinical significance of Routine Blood Test-Associated Inflammatory Index in Breast Cancer patients. Med Sci Monit. 2017;23:5090–5.CrossRefPubMedPubMedCentral Sun H, Yin CQ, Liu Q, Wang F, Yuan CH. Clinical significance of Routine Blood Test-Associated Inflammatory Index in Breast Cancer patients. Med Sci Monit. 2017;23:5090–5.CrossRefPubMedPubMedCentral
25.
go back to reference Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: shortterm friend, longterm foe. Clin Cancer Res. 2009;15:425–30.CrossRefPubMed Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: shortterm friend, longterm foe. Clin Cancer Res. 2009;15:425–30.CrossRefPubMed
26.
go back to reference Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–71.CrossRefPubMed Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–71.CrossRefPubMed
27.
go back to reference Kemal Y, Yucel I, Ekiz K, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in Lung cancer diagnosis[J]. Asian Pac J Cancer Prev. 2014;15(6):2651–4.CrossRefPubMed Kemal Y, Yucel I, Ekiz K, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in Lung cancer diagnosis[J]. Asian Pac J Cancer Prev. 2014;15(6):2651–4.CrossRefPubMed
28.
go back to reference Yoshida D, Minami K, Sugiyama M, et al. Prognostic impact of the neutrophil-to-lymphocyte ratio in stage I-II rectal Cancer Patients[J]. J Surg Res. 2020;245:281–7.CrossRefPubMed Yoshida D, Minami K, Sugiyama M, et al. Prognostic impact of the neutrophil-to-lymphocyte ratio in stage I-II rectal Cancer Patients[J]. J Surg Res. 2020;245:281–7.CrossRefPubMed
29.
go back to reference Miyamoto R, Inagawa S, Sano N, et al. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients[J]. Eur J Surg Oncol J Eur Soc Surg Oncol Br Association Surg Oncol. 2018;44(5):607–12. Miyamoto R, Inagawa S, Sano N, et al. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients[J]. Eur J Surg Oncol J Eur Soc Surg Oncol Br Association Surg Oncol. 2018;44(5):607–12.
30.
go back to reference Takenaka Y, Oya R, Kitamiura T, et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis. Head Neck. 2018;40(12):2714–23.CrossRefPubMed Takenaka Y, Oya R, Kitamiura T, et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis. Head Neck. 2018;40(12):2714–23.CrossRefPubMed
31.
go back to reference Yang J, Hsueh CY, Cao W, et al. Pretreatment lymphocyte-to-monocyte ratio as an Independent prognostic factor for hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 2018;138(8):734–40.CrossRefPubMed Yang J, Hsueh CY, Cao W, et al. Pretreatment lymphocyte-to-monocyte ratio as an Independent prognostic factor for hypopharyngeal squamous cell carcinoma. Acta Otolaryngol. 2018;138(8):734–40.CrossRefPubMed
32.
go back to reference Karaman M, Balta S, Seyit Ahmet AY, Cakar M, Naharci I, Demirkol S, Celik T, Arslan Z, Kurt O, Kocak N, Sarlak H, Demirbas S, Bulucu F, Bozoglu E. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed Hypertension. Clin Exp Hypertens. 2013;35(7):516–22.CrossRefPubMed Karaman M, Balta S, Seyit Ahmet AY, Cakar M, Naharci I, Demirkol S, Celik T, Arslan Z, Kurt O, Kocak N, Sarlak H, Demirbas S, Bulucu F, Bozoglu E. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed Hypertension. Clin Exp Hypertens. 2013;35(7):516–22.CrossRefPubMed
33.
go back to reference Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty Liver Disease. Liver Int. 2012;32(2):297–302.CrossRefPubMed Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty Liver Disease. Liver Int. 2012;32(2):297–302.CrossRefPubMed
34.
go back to reference Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M. Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost. 2013;19(5):579.CrossRefPubMed Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M. Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost. 2013;19(5):579.CrossRefPubMed
35.
go back to reference Dolan R, Mcsorley S, Horgan PG, et al. The role of the systematic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta analysis[J]. Crit Rev Oncol Hematol. 2017;116:134–46.CrossRefPubMed Dolan R, Mcsorley S, Horgan PG, et al. The role of the systematic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta analysis[J]. Crit Rev Oncol Hematol. 2017;116:134–46.CrossRefPubMed
36.
go back to reference Wu L, Saxena S, Singh RK. Neutrophils in the Tumor Microenvironment[J]. Advances in experimental medicine and biology. Adv Exp Med Biol. 2020;1224:1–20.CrossRefPubMedPubMedCentral Wu L, Saxena S, Singh RK. Neutrophils in the Tumor Microenvironment[J]. Advances in experimental medicine and biology. Adv Exp Med Biol. 2020;1224:1–20.CrossRefPubMedPubMedCentral
37.
go back to reference Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–72.CrossRefPubMed Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–72.CrossRefPubMed
38.
go back to reference Marcucci F, Stassi G, De Maria R. Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov. 2016;15(5):311–25.CrossRefPubMed Marcucci F, Stassi G, De Maria R. Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov. 2016;15(5):311–25.CrossRefPubMed
39.
40.
go back to reference Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873–98.CrossRefPubMed Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873–98.CrossRefPubMed
Metadata
Title
Correlation between preoperative peripheral blood NLR, PLR, LMR and prognosis of patients with head and neck squamous cell carcinoma
Authors
Jiao Zhou
Sheng Wei
Xiumei Guo
Yanjun Huang
Yizheng Zhang
Yuming Hong
Xiaofang Chen
Ming Lu
Feng Zheng
Chaohui Zheng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11752-y

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine